AAAAAA
Results:
1-15
|
Results: 15
Authors:
Vonderheide, RH
Dutcher, JP
Anderson, JE
Eckhardt, SG
Caron, DA
Gribben, JG
Citation: Rh. Vonderheide et al., Cd40 ligand therapy of lymphoma patients - Reply, J CL ONCOL, 19(23), 2001, pp. 4352-4353
Authors:
Vonderheide, RH
Dutcher, JP
Anderson, JE
Eckhardt, SG
Stephans, KF
Razvillas, B
Garl, S
Butine, MD
Perry, VP
Armitage, RJ
Ghalie, R
Caron, DA
Gribben, JG
Citation: Rh. Vonderheide et al., Phase I study of recombinant human CD40 ligand in cancer patients, J CL ONCOL, 19(13), 2001, pp. 3280-3287
Authors:
Dutcher, JP
Citation: Jp. Dutcher, Intravenous allopurinol in the prevention and treatment of tumor lysis syndrome - Introduction, SEMIN ONCOL, 28(2), 2001, pp. 1-2
Authors:
Unnikrishnan, D
Dutcher, JP
Varshneya, N
Lucariello, R
Wiernik, PH
Chiaramida, S
Citation: D. Unnikrishnan et al., Response: Monitoring of cardiac toxicity with arsenic trioxide, BLOOD, 98(5), 2001, pp. 1633-1634
Authors:
Unnikrishnan, D
Dutcher, JP
Varshneya, N
Lucariello, R
Api, M
Garl, S
Wiernik, PH
Chiaramida, S
Citation: D. Unnikrishnan et al., Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide, BLOOD, 97(5), 2001, pp. 1514-1516
Authors:
Dutcher, JP
Logan, T
Gordon, M
Sosman, J
Weiss, G
Margolin, K
Plasse, T
Mier, J
Lotze, M
Clark, J
Atkins, M
Citation: Jp. Dutcher et al., Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study, CLIN CANC R, 6(9), 2000, pp. 3442-3450
Authors:
Dutcher, JP
Novik, Y
O'Boyle, K
Marcoullis, G
Secco, C
Wiernik, PH
Citation: Jp. Dutcher et al., 20th-century advances in drug therapy in oncology - Part I, J CLIN PHAR, 40(9), 2000, pp. 1007-1024
Authors:
Dutcher, JP
Novik, Y
O'Boyle, K
Marcoullis, G
Secco, C
Wiernik, PH
Citation: Jp. Dutcher et al., 20th-century advances in drug therapy in oncology - Part II, J CLIN PHAR, 40(10), 2000, pp. 1079-1092
Authors:
Novik, Y
Ryan, LM
Haller, DG
Asbury, R
Dutcher, JP
Schutt, A
Citation: Y. Novik et al., Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282, MED ONCOL, 16(4), 1999, pp. 261-266
Authors:
Deshpande, H
Dutcher, JP
Novik, Y
Oleksowicz, L
Citation: H. Deshpande et al., Successful treatment of a patient on adrenal steroid replacement therapy high-dose bolus interleukin-2 for metastatic renal cell carcinoma, CA J SCI AM, 5(1), 1999, pp. 52-53
Authors:
Atkins, MB
Lotze, MT
Dutcher, JP
Fisher, RI
Weiss, G
Margolin, K
Abrams, J
Sznol, M
Parkinson, D
Hawkins, M
Paradise, C
Kunkel, L
Rosenberg, SA
Citation: Mb. Atkins et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993, J CL ONCOL, 17(7), 1999, pp. 2105-2116
Authors:
Oleksowicz, L
Dutcher, JP
Citation: L. Oleksowicz et Jp. Dutcher, A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma, J CANC RES, 125(2), 1999, pp. 101-108
Authors:
Dutcher, JP
Wiernik, PH
Citation: Jp. Dutcher et Ph. Wiernik, Novel biologic approaches to hematologic malignancies, CANC TREAT, 99, 1999, pp. 275-306
Authors:
Alpaugh, RK
von Mehren, M
Palazzo, I
Atkins, MB
Sparano, JA
Schuchter, L
Weiner, LM
Dutcher, JP
Citation: Rk. Alpaugh et al., Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon, MED ONCOL, 15(3), 1998, pp. 191-198
Authors:
Wu, JJ
Caliendo, G
Hu, XP
Dutcher, JP
Citation: Jj. Wu et al., Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma, MED ONCOL, 15(1), 1998, pp. 44-49
Risultati:
1-15
|